Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

[Image: see text] The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors in vitro; however, no anti-CK2 clinical approach has been investigated in COVID-19....

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, Leticia R., Baladrón, Idania, Rittoles, Aliusha, Díaz, Pablo A., Valenzuela, Carmen, Santana, Raúl, Vázquez, Maria M., García, Ariadna, Chacón, Deyli, Thompson, Delvin, Perera, Gustavo, González, Ariel, Reyes, Rafael, Torres, Loida, Pérez, Jesus, Valido, Yania, Rodriguez, Ralysmay, Vázquez-Bloomquist, Dania M., Rosales, Mauro, Ramón, Ailyn C., Pérez, George V., Guillén, Gerardo, Muzio, Verena, Perera, Yasser, Perea, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755077/
https://www.ncbi.nlm.nih.gov/pubmed/33615173
http://dx.doi.org/10.1021/acsptsci.0c00175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755077/
https://www.ncbi.nlm.nih.gov/pubmed/33615173
http://dx.doi.org/10.1021/acsptsci.0c00175

Ejemplares similares